SubsidieMeestersA revolutionary technology platform for providing life-saving treatment for end-stage heart failure patients
reBEAT is an innovative heart support technology that safely assists both sides of the heart, aiming to improve treatment accessibility and cost-effectiveness for end-stage heart failure patients.
Projectdetails
Introduction
Over 500K patients in the EU and US suffer from end-stage heart failure (HF), with a life expectancy of <1 year in 38% of cases. The prevalence of HF has increased recently, mainly due to improved survival after heart attacks. Such patients require mechanical support of their hearts.
Current Treatment Options
Available treatment options are:
- Heart transplantation (HTX)
- Ventricular assist device (VAD)
Today, <3% of these patients are treated due to donor heart shortages and restrictive employment of VADs. VADs can cause severe complications, such as bleeding and strokes, and typically only support one side of the heart.
reBEAT Technology
reBEAT is a revolutionary technology to mechanically support both sides of the heart. It has several advantages:
- Does not directly contact blood
- Can be easily implanted (~40 minutes)
- Presents virtually no contraindications for the patient population described
Cost Effectiveness
reBEAT offers high cost effectiveness at <50% of the cost of heart transplantations and VADs. AdjuCor expects revenues of 69M€ by 2027 with reBEAT.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.499.999 |
| Totale projectbegroting | € 3.912.949 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 31-12-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ADJUCOR GMBHpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Transcatheter Ventricular Repair Device for treatment of Heart Failure PatientsCardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing. | EIC Accelerator | € 2.500.000 | 2022 | Details |
ContraBand: the only heart failure medical device that is placed outside the heartContraBand is an implantable device designed to restore heart function in CHF patients, aiming for a 2024 launch and generating significant revenue while creating over 95 jobs in Europe. | EIC Accelerator | € 2.499.999 | 2022 | Details |
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoringThe Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations. | EIC Accelerator | € 2.299.633 | 2023 | Details |
The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the marketThe Realheart TAH system aims to provide a permanent, efficient, and adaptable artificial heart solution for end-stage heart failure patients, with trials planned for validation. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Commercialising a smart cardiac implant platform for the treatment of chronic cardiovascular diseaseAuriGen's platform aims to reduce chronic cardiac disease deaths and costs in Europe by providing advanced, multi-functional cardiac devices for effective, minimally invasive patient treatment. | EIC Accelerator | € 2.499.999 | 2023 | Details |
Transcatheter Ventricular Repair Device for treatment of Heart Failure Patients
Cardiac Success aims to develop the V-sling, a transcatheter device to enhance heart function in heart failure patients, through product optimization and pre-clinical testing.
ContraBand: the only heart failure medical device that is placed outside the heart
ContraBand is an implantable device designed to restore heart function in CHF patients, aiming for a 2024 launch and generating significant revenue while creating over 95 jobs in Europe.
Acorai Heart Monitor - Non-invasive multi-sensor device for heart failure monitoring
The Acorai Heart Monitor is a non-invasive device using machine learning to estimate cardiac pressure in heart failure patients, aiming to improve treatment outcomes and reduce hospitalizations.
The first Total Artificial Heart (TAH) that truly mimics the human heart and has the potential to revolutionise the market
The Realheart TAH system aims to provide a permanent, efficient, and adaptable artificial heart solution for end-stage heart failure patients, with trials planned for validation.
Commercialising a smart cardiac implant platform for the treatment of chronic cardiovascular disease
AuriGen's platform aims to reduce chronic cardiac disease deaths and costs in Europe by providing advanced, multi-functional cardiac devices for effective, minimally invasive patient treatment.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
SPARK - Subcutaneous Pump and Advanced Remote KitHet project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen. | Mkb-innovati... | € 199.138 | 2023 | Details |
CLOBT: Cardiale Levensreddende Ondersteuning Booster TechnoCardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten. | Mkb-innovati... | € 155.376 | 2020 | Details |
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac RepairTOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization. | ERC Proof of... | € 150.000 | 2023 | Details |
HeartGuard: Thuismonitoring van patiënt met hartfalen halveert aantal ziekenhuisopnamenDit project ontwikkelt een thuismonitoringsysteem voor hartfalenpatiënten dat met AI-gestuurde data-analyse ziekenhuisopnames met 44% kan verminderen en de zorg efficiënt verbetert. | Mkb-innovati... | € 332.500 | 2023 | Details |
Mechanical design concept for Cardiac Recovery Assist DeviceCardiacBooster ontwikkelt een veilig mechanisch device voor hartondersteuning bij acuut hartfalen, met focus op haalbaarheid en validatie via testen en samenwerking met derden. | Mkb-innovati... | € 20.000 | 2020 | Details |
SPARK - Subcutaneous Pump and Advanced Remote Kit
Het project ontwikkelt een innovatief hartondersteuningssysteem met een subcutane sensor voor betere behandeling van gevorderd hartfalen.
CLOBT: Cardiale Levensreddende Ondersteuning Booster Techno
CardiacBooster heeft een innovatief apparaat ontwikkeld dat het hart van binnenuit ondersteunt, met betere resultaten en minder risico's dan bestaande mechanische ondersteuningssystemen voor cardiogene shockpatiënten.
Technology Of Protein delivery in Extracellular Vesicle-induced Cardiac Repair
TOP-EVICARE aims to enhance cardiac repair in heart failure by developing innovative protein loading systems in extracellular vesicles, ensuring effective delivery and commercialization.
HeartGuard: Thuismonitoring van patiënt met hartfalen halveert aantal ziekenhuisopnamen
Dit project ontwikkelt een thuismonitoringsysteem voor hartfalenpatiënten dat met AI-gestuurde data-analyse ziekenhuisopnames met 44% kan verminderen en de zorg efficiënt verbetert.
Mechanical design concept for Cardiac Recovery Assist Device
CardiacBooster ontwikkelt een veilig mechanisch device voor hartondersteuning bij acuut hartfalen, met focus op haalbaarheid en validatie via testen en samenwerking met derden.